TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22449804

Group type: EXPERIMENTAL
Intervention: Xylitol lozenges (6 g/day) for 33 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-treatment (control group)
Number of subjects: 120
Study: 20040165

Group type: EXPERIMENTAL
Intervention: Nurse practitioner consultations
Number of subjects: 62

Group type: COMPARATOR
Intervention: GP consultations
Number of subjects: 62
Study: 18848670

Group type: EXPERIMENTAL
Intervention: Quick Start (QS) - immediate, directly observed OC pill ingestion in the clinic
Number of subjects: 539

Group type: COMPARATOR
Intervention: Conventional Start (CS) - conventional initiation of the OC pill
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 539
Study: 16100150

Group type: EXPERIMENTAL
Intervention: High-intensity constant work rate exercise at 65% of symptom-limited peak work rate
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High-intensity constant work rate exercise at 75% of symptom-limited peak work rate
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High-intensity constant work rate exercise at 85% of symptom-limited peak work rate
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High-intensity constant work rate exercise at 95% of symptom-limited peak work rate
Number of subjects: 27
Study: 12854936

Group type: EXPERIMENTAL
Intervention: Writing therapy intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 11324096

Group type: EXPERIMENTAL
Intervention: EARLY ALLIANCE interventions (integrated set of four programs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Universally administered classroom program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indicated, peer, reading-mentoring, and family programs
Number of subjects: 0
Study: 8983588

Group type: EXPERIMENTAL
Intervention: Radiation therapy (five different techniques used)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative seriality model of radiation response
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three-dimensional treatment planning system
Number of subjects: 0
Study: 1722779

Group type: EXPERIMENTAL
Intervention: HES‐A (500 ml daily for 9 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HES‐B (500 ml daily for 8 days)
Number of subjects: 60
Study: 7327086

Group type: EXPERIMENTAL
Intervention: Thrice weekly levo‐alpha‐acetylmethadol (LAAM)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Daily methadone
Number of subjects: 48
Study: 30182753

Group type: EXPERIMENTAL
Intervention: D3-Vitamin (100 μg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 29110854

Group type: EXPERIMENTAL
Intervention: erlotinib/sorafenib (400mg orally twice daily)
Number of subjects: 53

Group type: COMPARATOR
Intervention: sorafenib alone
Number of subjects: 53
Study: 26151421

Group type: EXPERIMENTAL
Intervention: 600,000 IU intramuscular (i.m.)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 600,000 IU oral (p.o.)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 200,000 IU intramuscular (i.m.)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 200,000 IU oral (p.o.)
Number of subjects: 100
Study: 22872657

Group type: EXPERIMENTAL
Intervention: Slow intravenous infusion of lactated Ringer solution (1.2 ± 0.3 litres)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dehydration (no intravenous infusion)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normothermic time control
Number of subjects: 8
Study: 21084202

Group type: EXPERIMENTAL
Intervention: taliglucerase alfa (novel plant-cell-derived recombinant enzyme)
Number of subjects: 31
Study: 19213607

Group type: EXPERIMENTAL
Intervention: Brachytherapy I-125 with rectal protection using hyaluronic acid (HA)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Brachytherapy I-125 alone without HA
Number of subjects: 69
Study: 17941364

Group type: EXPERIMENTAL
Intervention: Avène Thermal Spring Water (PDT or IPL)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: NIA 24 (PDT or IPL)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: MimyX cream (PDT or IPL)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Biafine (PDT or IPL)
Number of subjects: 4
Study: 15551893

Group type: EXPERIMENTAL
Intervention: 5 mg midazolam (1 ml)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 3 mg midazolam (1 ml)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Normal saline (1 ml) as placebo
Number of subjects: 53
Study: 14527807

Group type: EXPERIMENTAL
Intervention: Voluntary load drop
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Known timing of load release
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Unknown timing of load release
Number of subjects: 11
Study: 10437420

Group type: EXPERIMENTAL
Intervention: Gabapentin (900-1200 mg daily)
Number of subjects: 18
Study: 7559310

Group type: EXPERIMENTAL
Intervention: PTSD in parents
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Depressive disorders in parents
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Environmental variables
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Onset of PTSD symptoms
Number of subjects: 209
Study: 2322970

Group type: EXPERIMENTAL
Intervention: 3 ml, 1.5 per cent lidocaine hydrochloride injected through the needle prior to catheter insertion
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 3 ml saline injected prior to catheter insertion
Number of subjects: 200

Group type: COMPARATOR
Intervention: Catheter inserted without previous injection of fluid
Number of subjects: 200
Study: 7010262

Group type: EXPERIMENTAL
Intervention: Tiopronin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 31479563

Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 4106

Group type: EXPERIMENTAL
Intervention: Dutasteride arm (statin users)
Number of subjects: 4106

Group type: COMPARATOR
Intervention: Placebo arm (statin users)
Number of subjects: 4106
Study: 31675942

Group type: EXPERIMENTAL
Intervention: Healthy Heroes Activity Pack delivered over 6 months
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cluster level intervention (staff training using Be Active, Eat Healthy)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Parent-reported outcomes
Number of subjects: 81
Study: 28735785

Group type: EXPERIMENTAL
Intervention: Simultaneous length control during root canal preparation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Separate length determination and root canal preparation (Control)
Number of subjects: 44
Study: 25981742

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Stretch exercise (control)
Number of subjects: 10
Study: 23513246

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) oxygen therapy at 30 L/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) oxygen therapy at 40 L/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) oxygen therapy at 50 L/min
Number of subjects: 0
Study: 21736780

Group type: EXPERIMENTAL
Intervention: Daily supplemented with 600 μg retinol, 1·0 mg β‐carotene, 100 mg tocopherol, 300 mg ascorbic acid and 200 μg Se (Group A2)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Daily supplemented with 900 μg retinol, 1·5 mg β‐carotene, 200 mg tocopherol, 500 mg ascorbic acid and 400 μg Se (Groups B2 and C2)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo-controlled (Groups A1, B1, C1)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Daily supplemented with antioxidants (Groups B2 and C2)
Number of subjects: 254
Study: 19135997

Group type: EXPERIMENTAL
Intervention: Fast-track program
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Fluid administration greater than restriction limits
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Nonfunctioning epidural analgesia
Number of subjects: 156
Study: 17693690

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate (LC) diet
Number of subjects: 1

Group type: COMPARATOR
Intervention: Grain-Based (GB) diet
Number of subjects: 1
Study: 14551140

Group type: EXPERIMENTAL
Intervention: 10 mg/kg IDEC‐131/E6040
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5 mg/kg IDEC‐131/E6040
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1 mg/kg IDEC‐131/E6040
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2 mg/kg IDEC‐131/E6040
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 11382722

Group type: EXPERIMENTAL
Intervention: Combination therapy with abciximab
Number of subjects: 2394
Study: 9458300

Group type: EXPERIMENTAL
Intervention: Transverse colon interposition (TCI)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Roux en Y anastomosis (R-Y anastomosis)
Number of subjects: 133
Study: 8023659

Group type: EXPERIMENTAL
Intervention: Lumbar epidural administration of 50 micrograms sufentanil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thoracic epidural administration of 50 micrograms sufentanil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (not explicitly defined)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lumbar group with 75 micrograms sufentanil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thoracic group with 75 micrograms sufentanil
Number of subjects: 30
Study: 31829457

Group type: EXPERIMENTAL
Intervention: Dynamic navigation device
Number of subjects: 32

Group type: COMPARATOR
Intervention: Freehand method
Number of subjects: 32
Study: 31198939

Group type: EXPERIMENTAL
Intervention: XAP + probiotics (2,000 U xylanase + 200 U amylase + 4,000 U protease/kg diet + 75,000 CFU/g of Bacillus spp.)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: XAP (2,000 U xylanase + 200 U amylase + 4,000 U protease/kg diet)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: XAP + probiotics
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no supplements)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: XAP
Number of subjects: 48
Study: 25346391

Group type: EXPERIMENTAL
Intervention: Interpersonal and social rhythm therapy (IPSRT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Specialist supportive care (SSC)
Number of subjects: 100
Study: 23587564

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily
Number of subjects: 1617

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1617
Study: 18478229

Group type: EXPERIMENTAL
Intervention: Open nidus resection guided by a hand‐held gamma probe
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 53
Study: 17558358

Group type: EXPERIMENTAL
Intervention: Upper extremity use in hemiparetic subjects
Number of subjects: 34

Group type: COMPARATOR
Intervention: Upper extremity use in healthy control subjects
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Impairment measures related to upper extremity use
Number of subjects: 34
Study: 16163159

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 0
Study: 11981152

Group type: COMPARATOR
Intervention: Bupivacaine alone (0.091% wt/vol)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine 1:300,000 (66.7 microg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine
Number of subjects: 70
Study: 9857856

Group type: EXPERIMENTAL
Intervention: 10 mg imidapril
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: 5 mg imidapril
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: 2.5 mg imidapril
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: All doses of imidapril
Number of subjects: 244
Study: 8848531

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2227631

Group type: EXPERIMENTAL
Intervention: Norfloxacin (NOR)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Cotrimoxazole (TMP/SMX)
Number of subjects: 59
Study: 472338

Group type: EXPERIMENTAL
Intervention: Indomethacin pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: PGE2 infusion
Number of subjects: 0
Study: 31804890

Group type: EXPERIMENTAL
Intervention: Acetazolamide (AZ) 500 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study: 30238964

Group type: EXPERIMENTAL
Intervention: Teachers' SEL Belief Scale
Number of subjects: 432
Study: 28206704

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks (Q2W), increased to 150 mg Q2W at Week 12 if Week 8 LDL-C was ≥70 mg/dL
Number of subjects: 720

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg daily
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Alirocumab and Ezetimibe (both groups)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 720
Study: 25312605

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation programme (four-week home-based)
Number of subjects: 15
Study: 23150188

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (EGB 761) 60 mg twice daily
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 21050797

Group type: EXPERIMENTAL
Intervention: Physiological technique
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Technique with addition of a transverse directed force
Number of subjects: 15
Study: 19887683

Group type: EXPERIMENTAL
Intervention: Remineralizing cream containing casein phosphopeptide-amorphous calcium phosphate
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 17448130

Group type: EXPERIMENTAL
Intervention: Metformin alone
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Metformin + Rosiglitazone
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Metformin + Intensive Lifestyle Intervention
Number of subjects: 800
Study: 15343602

Group type: EXPERIMENTAL
Intervention: Color Doppler analysis
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Color spectral Doppler parameters
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Highest PSV
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: PSV
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Median relative color
Number of subjects: 74

Group type: COMPARATOR
Intervention: 3D color power angiography parameters
Number of subjects: 74
Study: 12243825

Group type: EXPERIMENTAL
Intervention: GM-CSF mouthwashes (37.5 microg GM-CSF, 4 times daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sucralfate mouthwashes (1.0 g sucralfate, 4 times daily)
Number of subjects: 40
Study: 9852907

Group type: EXPERIMENTAL
Intervention: Adenosine 15 mumol/L
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Adenosine 50 mumol/L
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Adenosine 100 mumol/L
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study: 7537722

Group type: EXPERIMENTAL
Intervention: Ziehl‐Neelsen staining method
Number of subjects: 306

Group type: COMPARATOR
Intervention: Cold staining method
Number of subjects: 306
Study: 2913914

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.43 micrograms/d)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 30640483

Group type: EXPERIMENTAL
Intervention: DADEE program (9 weekly educational and practical sessions plus home-based challenges)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: DADEE program
Number of subjects: 153

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 153
Study: 27923444

Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle intervention (seven group sessions on healthy diet and physical activity)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 96
Study: 25838092

Group type: EXPERIMENTAL
Intervention: OIT with Cry j1-galactomannan conjugate
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no OIT)
Number of subjects: 47
Study: 24163189

Group type: EXPERIMENTAL
Intervention: 4,250 IU/day of parnaparin
Number of subjects: 258

Group type: COMPARATOR
Intervention: 6,400 IU/day of parnaparin
Number of subjects: 258
Study: 21083590

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg for 2 weeks
Number of subjects: 805

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 805
Study: 19185245

Group type: EXPERIMENTAL
Intervention: Endoilluminator-assisted group (transillumination technique)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (transscleral fixation without transillumination)
Number of subjects: 33
Study: 20084725

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (cisplatin 80 mg/m2 on day 1 and Gemcitabine 1250 mg/m2 on days 1 and 8, every 3 weeks) followed by radiotherapy (60 Gy/30 fractions/6 weeks)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Radiotherapy alone (60 Gy/30 fractions/6 weeks)
Number of subjects: 69
Study: 15955041

Group type: EXPERIMENTAL
Intervention: Migraine patients without aura
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Migraine patients who took a triptan within 3 days prior to investigation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 12117292

Group type: EXPERIMENTAL
Intervention: Cellulose diacetate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Polysulfone
Number of subjects: 10

Group type: COMPARATOR
Intervention: EVAL
Number of subjects: 10
Study: 9669077

Group type: EXPERIMENTAL
Intervention: Xylocaine (lidocaine) spray
Number of subjects: 82

Group type: COMPARATOR
Intervention: Normal saline spray
Number of subjects: 82

Group type: COMPARATOR
Intervention: No spray
Number of subjects: 82
Study: 7641121

Group type: EXPERIMENTAL
Intervention: Tenormin (100 mg once daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tenolol (100 mg once daily)
Number of subjects: 23
Study: 2650646

Group type: EXPERIMENTAL
Intervention: Sodium warfarin
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 742832

Group type: EXPERIMENTAL
Intervention: Elevated serum bilirubin
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Elevated aminotransferases
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Elevated alkaline phosphatase
Number of subjects: 155

Group type: COMPARATOR
Intervention: Delayed surgery
Number of subjects: 155

Group type: COMPARATOR
Intervention: Early surgery
Number of subjects: 155
Study: 30307122

Group type: EXPERIMENTAL
Intervention: 7-day STT (rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 7 days)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: 7-day STT with bismuth (rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, bismuth subcitrate 240 mg twice daily for 7 days)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: 14-day STT (rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 14 days)
Number of subjects: 364
Study: 25604851

Group type: EXPERIMENTAL
Intervention: mDCF regimen (docetaxel 60 mg/m² on day 1, cisplatin 60 mg/m² on day 1, fluorouracil 600 mg/m²/day on days 1-5)
Number of subjects: 243

Group type: COMPARATOR
Intervention: CF regimen (cisplatin 75 mg/m² on day 1, fluorouracil 600 mg/m²/day on days 1-5)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: mDCF regimen
Number of subjects: 243

Group type: COMPARATOR
Intervention: CF regimen
Number of subjects: 243
Study: 25348033

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 200 to 400 mg per day
Number of subjects: 510

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study: 21910711

Group type: EXPERIMENTAL
Intervention: BF-200 ALA
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600

Group type: COMPARATOR
Intervention: MAL cream
Number of subjects: 600
Study: 19748251

Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate (5MTHF)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 22
Study: 18459010

Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/day for the first 2 years and 10 mg/day thereafter)
Number of subjects: 2785

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2785
Study: 15925438

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasonography
Number of subjects: 110

Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 110
Study: 12473087

Group type: EXPERIMENTAL
Intervention: Physostigmine (cholinesterase inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 10630045

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: No drug (Control)
Number of subjects: 0
Study: 8550722

Group type: EXPERIMENTAL
Intervention: Conversational turn-taking
Number of subjects: 14

Group type: COMPARATOR
Intervention: Random responsiveness
Number of subjects: 14
Study: 1960558

Group type: EXPERIMENTAL
Intervention: DAVTH (mitolactol, doxorubicin, vincristine, tamoxifen, fluoxymesterone)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: DAVTH
Number of subjects: 501

Group type: COMPARATOR
Intervention: Ineligible patients
Number of subjects: 501
Study: 6758494

Group type: EXPERIMENTAL
Intervention: Apple
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Banana
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orange
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pure glucose
Number of subjects: 0
Study: 30264259

Group type: EXPERIMENTAL
Intervention: Health coaching for disease management from Bupa Health Dialog
Number of subjects: 44418

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 44418
Study: 28933133

Group type: EXPERIMENTAL
Intervention: Nerve mobilization exercises
Number of subjects: 12

Group type: COMPARATOR
Intervention: Gentle joint mobilization exercises
Number of subjects: 12